SAR-CoV-2

[키워드] 1:1 Adults age all-cause mortality Ambulatory care Analysis anti-bacterial Anti-inflammatory anti-inflammatory properties antibiotic antiviral properties antiviral property Azithromycin Bacterial infection Biomarkers Blood Care Clinical diagnosis clinical trial clinical utility clinically Coronavirus disease 2019 Coronavirus infections Course COVID-19 COVID-19 infection COVID-19 symptoms cytokine Cytokines death determine diagnosed disease early disease EudraCT Follow-up G-CSF GM-CSF hospital include initial Interleukins invasive Macrolide management mechanical ventilation MERS-CoV moderate moderate to severe Mortality multi nasal Non-invasive non-invasive mechanical ventilation ongoing trial Open-label Opened Other pandemic coronavirus participant pathway Patient PCR-confirmed PCR-confirmed diagnosis presenting pro-inflammatory cytokine pro-inflammatory cytokines progression proportion randomisation randomised reduce Respiratory failure risk Safe SAR-CoV-2 SARS-CoV secondary bacterial infection Secondary objective Secondary objectives severe disease severe pneumonia severe SARS severity severity of illness standard care Study protocol suppression Symptom Symptoms Therapeutic benefit therapy treat Trial Trial registration Two-arm usual care with COVID-19
[DOI] 10.1186/s13063-020-04593-8 PMC 바로가기 [Article Type] Study Protocol